A detailed history of Tower Research Capital LLC (Trc) transactions in Immunome Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,479 shares of IMNM stock, worth $16,224. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,479
Previous 2,002 26.12%
Holding current value
$16,224
Previous $24,000 12.5%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$11.7 - $16.51 $6,119 - $8,634
-523 Reduced 26.12%
1,479 $21,000
Q2 2024

Aug 13, 2024

BUY
$11.54 - $22.11 $10,489 - $20,097
909 Added 83.17%
2,002 $24,000
Q1 2024

May 15, 2024

BUY
$11.01 - $27.34 $12,033 - $29,882
1,093 New
1,093 $26,000
Q2 2023

Aug 14, 2023

BUY
$4.7 - $7.91 $8,046 - $13,541
1,712 Added 128.92%
3,040 $24,000
Q1 2023

May 09, 2023

SELL
$3.26 - $5.69 $3,357 - $5,860
-1,030 Reduced 43.68%
1,328 $7,000
Q4 2022

Feb 10, 2023

BUY
$2.21 - $5.0 $5,211 - $11,790
2,358 New
2,358 $5,000
Q2 2022

Aug 15, 2022

BUY
$2.24 - $5.79 $5,279 - $13,647
2,357 Added 1785.61%
2,489 $8,000
Q1 2022

May 12, 2022

SELL
$3.88 - $13.99 $3,080 - $11,108
-794 Reduced 85.75%
132 $1,000
Q4 2021

Feb 14, 2022

BUY
$12.96 - $23.44 $12,000 - $21,705
926 New
926 $12,000
Q3 2021

Nov 15, 2021

SELL
$12.5 - $27.76 $1,250 - $2,776
-100 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$16.33 - $32.33 $51,096 - $101,160
-3,129 Reduced 96.9%
100 $2,000
Q1 2021

May 17, 2021

SELL
$9.56 - $43.24 $17,599 - $79,604
-1,841 Reduced 36.31%
3,229 $110,000
Q4 2020

Feb 16, 2021

BUY
$9.46 - $14.16 $47,962 - $71,791
5,070 New
5,070 $49,000

Others Institutions Holding IMNM

About Immunome Inc.


  • Ticker IMNM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,127,400
  • Market Cap $133M
  • Description
  • Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...
More about IMNM
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.